A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Cancer vaccines targeting self-antigens face challenges due to immunological tolerance.
• Developing effective immunotherapies against tumors expressing self-antigens remains a critical need.

Purpose of the Study:

• To investigate a novel naked DNA vaccine strategy using a ubiquitin-fused self-antigen to break tolerance and induce anti-tumor immunity.
• To evaluate the efficacy of this vaccine in a preclinical melanoma model.

Main Methods:

• A naked DNA vaccine encoding tyrosinase-related protein 2 (TRP2) with a fused ubiquitin moiety was constructed.
• The vaccine's ability to induce protective immunity and therapeutic effects against melanoma was assessed in C57BL/6 mice.
• The role of the ubiquitin-proteasome pathway was investigated using proteasome activator PA28alpha/beta knockout mice.

Main Results:

• The ubiquitin-fused DNA vaccine successfully broke immunological tolerance and induced protective immunity against melanoma.
• Significant improvements in tumor growth, survival rates, and reduced lung metastasis were observed.
• Immunity was abrogated in proteasome activator PA28alpha/beta knockout mice, highlighting the pathway's importance.
• The vaccination demonstrated therapeutic effects on established melanoma.

Conclusions:

• Naked DNA vaccines encoding ubiquitin-fused self-antigens can effectively break tolerance and induce robust CD8+ T cell responses.
• This approach utilizes the ubiquitin-proteasome pathway for enhanced antigen presentation, leading to potent anti-tumor immunity.
• This strategy holds promise for developing novel cancer vaccines targeting tissue differentiation antigens.